Why Kura Oncology, Inc.’s (KURA) Stock Is Down 5.05%
As of Wednesday, July 29, Kura Oncology, Inc.’s KURA share price has dipped by 5.05%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Commentary & Analysis
Why Kura Oncology, Inc.’s (KURA) Stock Is Down 7.49%
As of Tuesday, July 28, Kura Oncology, Inc.’s KURA share price has dipped by 7.49%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Kura Oncology, Inc.’s (KURA) Stock Is Down 5.34%
As of Friday, July 10, Kura Oncology, Inc.’s KURA share price has dipped by 5.34%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Kura Oncology, Inc.’s (KURA) Stock Is Up 6.70%
As of Tuesday, July 07, Kura Oncology, Inc.’s KURA share price has surged by 6.70%, which has investors questioning if this is right time to sell.Michael Rose
Why Kura Oncology, Inc.’s (KURA) Stock Is Up 5.59%
As of Monday, June 22, Kura Oncology, Inc.’s KURA share price has surged by 5.59%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | KURA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $799.9 | $252.6 | 43% |
|
| Shares Out (Mil) | 88.6 | 52.3 | 60% |
|
| Institutional Ownership | 98.1% | 92.1% | 77% |
|
| Float (Mil) | 70.4 | 40.2 | 55% |
|
| Beta | 0.32 | 0.95 | 18% |
|
| Avg Daily Volume (000s) | 1,180 | 455 | 74% |
|
| Price Change (52-week) |
43.0% | 52.9% | 77% |
|
| Growth | KURA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (25.5%) | (9.9%) | 16% |
|
| EPS (5yr) | (13.5%) | 16.0% | 19 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.6%) | (15.6%) | 43% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 9 | 9 | |
| Current EPS | ($0.876) | ($3.442) | ($2.580) | |
| Month Ago EPS | ($0.886) | ($3.457) | ($2.598) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 2 | 0 | 1 | |
| Three Months Ago EPS | ($0.957) | ($3.426) | ($2.506) | |
| Year/Year Chg | 5.8% | 8.3% | (35.7%) | |
| Financials | KURA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $72 | $38 | 23% |
|
| Net Income (TTM) (Mil) | ($295) | ($43) | 5% |
|
| EPS (TTM) | ($3.348) | ($1.600) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($78) | ($31) | 7% |
|
| Net Cash Flow (TTM) (Mil) | ($12) | $5 | 29% |
|
| Long-Term Debt (Q1) (Mil) | $23 | $5 | 34% |
|
| Enterprise Value (Q1) (Mil) | $285 | $180 | 29% |
|
| Valuation | KURA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 7.39 | 2.56 | 86% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | KURA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (263.9%) | 63.8% | 1% |
|
| Net Margin | (411.2%) | (67.3%) | 2% |
|
| ROA | (42.2%) | (49.8%) | 13% |
|
| ROE | (124.7%) | (55.5%) | 8% |
|
| Liabilities to Assets | 83.5% | 30.3% | 77% |
|
| F-Score | 1 | 3 | 1% |
|
Kura Oncology, Inc. did not pass any screens on 7/31/2026.
